There are now several multi-kinase and FLT3 inhibitors approved for the treatment of FLT3-mutated AML in the pre-alloHSCT setting, and there has been interest in studying these inhibitors in the peri-and post-transplant setting, with relevant agents including sorafenib, midostaurin, gilteritinib, and quizartinib. This evidence concerns the gene FLT3 and acute myeloid leukemia.